Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin …

CA Bousman, JM Stevenson… - Clinical …, 2023 - Wiley Online Library
Serotonin reuptake inhibitor antidepressants, including selective serotonin reuptake
inhibitors (SSRIs; ie, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and …

Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017

C Hiemke, N Bergemann, HW Clement… - …, 2018 - thieme-connect.com
Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug
concentrations in blood to optimize pharmacotherapy. It considers the interindividual …

Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology

OD Howes, R McCutcheon, O Agid… - American Journal of …, 2017 - Am Psychiatric Assoc
Objective: Research and clinical translation in schizophrenia is limited by inconsistent
definitions of treatment resistance and response. To address this issue, the authors …

[HTML][HTML] Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants …

JK Hicks, K Sangkuhl, JJ Swen… - Clinical …, 2017 - ncbi.nlm.nih.gov
Abstract CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of
tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (eg …

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake …

JK Hicks, JR Bishop, K Sangkuhl… - Clinical …, 2015 - Wiley Online Library
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major
depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the …

Nutraceuticals in neurological disorders

R Makkar, T Behl, S Bungau, G Zengin… - International journal of …, 2020 - mdpi.com
Neurological diseases are one of the major healthcare issues worldwide. Posed lifestyle
changes are associated with drastically increased risk of chronic illness and diseases …

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute …

M Bauer, A Pfennig, E Severus… - The world journal of …, 2013 - Taylor & Francis
Objectives. This 2013 update of the practice guidelines for the biological treatment of
unipolar depressive disorders was developed by an international Task Force of the World …

Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics

M Schulz, S Iwersen-Bergmann, H Andresen… - Critical care, 2012 - Springer
Introduction In order to assess the significance of drug levels measured in intensive care
medicine, clinical and forensic toxicology, as well as for therapeutic drug monitoring, it is …

Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF randomized clinical trial

CE Angermann, G Gelbrich, S Störk, H Gunold… - Jama, 2016 - jamanetwork.com
Importance Depression is frequent in patients with heart failure and is associated with
adverse clinical outcomes. Long-term efficacy and safety of selective serotonin reuptake …

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

JK Hicks, JJ Swen, CF Thorn… - Clinical …, 2013 - Wiley Online Library
Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with
some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes …